<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00896376</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000626782</org_study_id>
    <secondary_id>CALACASS-2005/35</secondary_id>
    <secondary_id>CALACASS-PHRC 2005 Herceptine</secondary_id>
    <secondary_id>INCA-RECF0618</secondary_id>
    <nct_id>NCT00896376</nct_id>
  </id_info>
  <brief_title>Trastuzumab in Treating Women With Metastatic Breast Cancer</brief_title>
  <official_title>Prospective Multicenter Study of Genetic Factors Predictive of the Pharmacodynamics of Trastuzumab in Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Antoine Lacassagne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Antoine Lacassagne</source>
  <brief_summary>
    <textblock>
      RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help&#xD;
      doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.&#xD;
      It may also help doctors predict how patients will respond to treatment.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying the side effects of trastuzumab in treating women&#xD;
      with metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To evaluate the predictive value of genetic factors on the toxicity and efficacy of a&#xD;
           trastuzumab-based therapy in women with metastatic breast cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To analyze tumor factors potentially related to the efficacy of trastuzumab (i.e.,&#xD;
           expression of proteins involved in cell proliferation and survival).&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive standard treatment with trastuzumab. Blood is collected periodically for&#xD;
      pharmacogenetic analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity, including cardiotoxicity and immuno-allergic reactions</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical response as assessed by RECIST criteria</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>trastuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>trastuzumab</intervention_name>
    <arm_group_label>trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <arm_group_label>trastuzumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <arm_group_label>trastuzumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed breast cancer&#xD;
&#xD;
               -  Metastatic disease, defined by the existence of a secondary tumor localization&#xD;
                  radiologically (i.e., by radiography, CT scan, MRI scan, or ultrasound) or&#xD;
                  scintigraphically confrimed&#xD;
&#xD;
          -  Evaluable disease&#xD;
&#xD;
          -  Beginning first-line metastatic treatment with trastuzumab (HerceptinÂ®) with or&#xD;
             without chemotherapy&#xD;
&#xD;
          -  Primary tumor must overexpress HER2 (IHC 3+ OR IHC 2+ and FISH+ OR FISH+)&#xD;
&#xD;
          -  Hormone receptor status not specified&#xD;
&#xD;
          -  No brain metastasis&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Able to undergo cardiotoxicity evaluation every 4 months by measuring LVEF via an&#xD;
             isotopic method or ultrasound with systematic registration&#xD;
&#xD;
          -  No chronic uncontrolled disease&#xD;
&#xD;
          -  No heart failure&#xD;
&#xD;
          -  No respiratory failure or hypoxemia&#xD;
&#xD;
          -  No history of another primary cancer except for basal cell carcinoma of the skin&#xD;
&#xD;
          -  No severe uncontrolled infection&#xD;
&#xD;
          -  No psychological incapacity&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Marc Ferrero, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Antoine Lacassagne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>May 8, 2009</study_first_submitted>
  <study_first_submitted_qc>May 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 11, 2009</study_first_posted>
  <last_update_submitted>February 8, 2015</last_update_submitted>
  <last_update_submitted_qc>February 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>HER2-positive breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

